Literature DB >> 9130925

Hyperinsulinism in infants and children.

C A Stanley1.   

Abstract

Hyperinsulinism is the most common cause of hypoglycemia in early infancy. Congenital hyperinsulinism, formerly termed nesidioblastosis, is usually caused by genetic defects in beta-cell regulation, including a severe recessive disorder of the sulfonylurea receptor, a milder dominant form of hyperinsulinism, and a syndrome of hyperinsulinism plus hyperammonemia. Transient neonatal hyperinsulinism may be associated with perinatal asphyxia or small-for-dates birthweight and maternal diabetes. To prevent permanent brain damage from hypoglycemia, the treatment of infants with hyperinsulinism must be prompt and aggressive. A combination of medical therapy with diazoxide or octreotide, a long-acting somatostatin analog, and surgical 95% subtotal pancreatectomy may be required.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130925     DOI: 10.1016/s0031-3955(05)70481-8

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  26 in total

Review 1.  Hyperinsulinism and Beckwith-Wiedemann syndrome.

Authors:  C F Munns; J A Batch
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-01       Impact factor: 5.747

2.  Calcium-stimulated insulin secretion in diffuse and focal forms of congenital hyperinsulinism.

Authors:  R J Ferry; A Kelly; A Grimberg; S Koo-McCoy; M J Shapiro; K E Fellows; B Glaser; L Aguilar-Bryan; D E Stafford; C A Stanley
Journal:  J Pediatr       Date:  2000-08       Impact factor: 4.406

3.  Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations.

Authors:  A Grimberg; R J Ferry; A Kelly; S Koo-McCoy; K Polonsky; B Glaser; M A Permutt; L Aguilar-Bryan; D Stafford; P S Thornton; L Baker; C A Stanley
Journal:  Diabetes       Date:  2001-02       Impact factor: 9.461

4.  Allosteric discrimination at the NADH/ADP regulatory site of glutamate dehydrogenase.

Authors:  Omneya M Nassar; Ka-Yiu Wong; Gillian C Lynch; Thomas J Smith; B Montgomery Pettitt
Journal:  Protein Sci       Date:  2019-11-01       Impact factor: 6.725

5.  3-hydroxyacyl-coenzyme a dehydrogenase deficiency: identification of a new mutation causing hyperinsulinemic hypoketotic hypoglycemia, altered organic acids and acylcarnitines concentrations.

Authors:  Florina Ion Popa; Silvia Perlini; Francesca Teofoli; Daniela Degani; Silvia Funghini; Giancarlo La Marca; Piero Rinaldo; Monica Vincenzi; Franco Antoniazzi; Attilio Boner; Marta Camilot
Journal:  JIMD Rep       Date:  2011-09-06

6.  Membrane phosphoinositides control insulin secretion through their effects on ATP-sensitive K+ channel activity.

Authors:  Chia-Wei Lin; Feifei Yan; Satoko Shimamura; Sebastian Barg; Show-Ling Shyng
Journal:  Diabetes       Date:  2005-10       Impact factor: 9.461

7.  Pancreatic head resection and Roux-en-Y pancreaticojejunostomy for the treatment of the focal form of congenital hyperinsulinism.

Authors:  Pablo Laje; Charles A Stanley; Andrew A Palladino; Susan A Becker; N Scott Adzick
Journal:  J Pediatr Surg       Date:  2012-01       Impact factor: 2.545

8.  Congenital hyperinsulinism associated ABCC8 mutations that cause defective trafficking of ATP-sensitive K+ channels: identification and rescue.

Authors:  Fei-Fei Yan; Yu-Wen Lin; Courtney MacMullen; Arupa Ganguly; Charles A Stanley; Show-Ling Shyng
Journal:  Diabetes       Date:  2007-06-15       Impact factor: 9.461

9.  Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide.

Authors:  Paul I Pelavin; Erika Abramson; Steven Pon; Maria G Vogiatzi
Journal:  J Pediatr Endocrinol Metab       Date:  2009-02       Impact factor: 1.634

10.  Pancreatic head resection preserving the main pancreatic duct for congenital hyperinsulinism of infancy.

Authors:  Masayuki Obatake; Kyoko Mochizuki; Yasuaki Taura; Yukio Inamura; Akiko Nakatomi; Fumiko Kinoshita; Takeshi Nagayasu
Journal:  Pediatr Surg Int       Date:  2012-09       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.